Cargando…

Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons

BACKGROUND: Uptake of Isoniazid Preventive Therapy (IPT) among People Living with HIV in Zambia has continued to be low despite various evidence for its added benefit in reducing TB incidence and mortality when taken with antiretroviral therapy. In 2017, only 18% of People Living with HIV newly enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagujje, Mary, Mubiana, Muhau L., Mwamba, Eugenia, Muyoyeta, Monde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805296/
https://www.ncbi.nlm.nih.gov/pubmed/31640657
http://dx.doi.org/10.1186/s12889-019-7652-x
_version_ 1783461348992090112
author Kagujje, Mary
Mubiana, Muhau L.
Mwamba, Eugenia
Muyoyeta, Monde
author_facet Kagujje, Mary
Mubiana, Muhau L.
Mwamba, Eugenia
Muyoyeta, Monde
author_sort Kagujje, Mary
collection PubMed
description BACKGROUND: Uptake of Isoniazid Preventive Therapy (IPT) among People Living with HIV in Zambia has continued to be low despite various evidence for its added benefit in reducing TB incidence and mortality when taken with antiretroviral therapy. In 2017, only 18% of People Living with HIV newly enrolled in care were initiated on IPT in Zambia. MAIN TEXT: Various challenges including policy and management level factors, supply chain factors, health worker perceptions about IPT, monitoring and evaluation factors and limited demand creation activities have constrained the scale up of IPT in Zambia. Lessons that have been learnt while addressing the above challenges are shared and they can be applied by government ministries, project managers, public health specialists to strengthen IPT activities in their settings. CONCLUSION: Zambia has both a high burden of TB and HIV and without preventing new cases of TB from reactivation of latent TB infection, it will be difficult to control TB. All stakeholders involved in prevention of TB among PLHIV need to commit to addressing the challenges limiting scale up of IPT.
format Online
Article
Text
id pubmed-6805296
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68052962019-10-24 Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons Kagujje, Mary Mubiana, Muhau L. Mwamba, Eugenia Muyoyeta, Monde BMC Public Health Debate BACKGROUND: Uptake of Isoniazid Preventive Therapy (IPT) among People Living with HIV in Zambia has continued to be low despite various evidence for its added benefit in reducing TB incidence and mortality when taken with antiretroviral therapy. In 2017, only 18% of People Living with HIV newly enrolled in care were initiated on IPT in Zambia. MAIN TEXT: Various challenges including policy and management level factors, supply chain factors, health worker perceptions about IPT, monitoring and evaluation factors and limited demand creation activities have constrained the scale up of IPT in Zambia. Lessons that have been learnt while addressing the above challenges are shared and they can be applied by government ministries, project managers, public health specialists to strengthen IPT activities in their settings. CONCLUSION: Zambia has both a high burden of TB and HIV and without preventing new cases of TB from reactivation of latent TB infection, it will be difficult to control TB. All stakeholders involved in prevention of TB among PLHIV need to commit to addressing the challenges limiting scale up of IPT. BioMed Central 2019-10-22 /pmc/articles/PMC6805296/ /pubmed/31640657 http://dx.doi.org/10.1186/s12889-019-7652-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Kagujje, Mary
Mubiana, Muhau L.
Mwamba, Eugenia
Muyoyeta, Monde
Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
title Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
title_full Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
title_fullStr Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
title_full_unstemmed Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
title_short Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
title_sort implementation of isoniazid preventive therapy in people living with hiv in zambia: challenges and lessons
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805296/
https://www.ncbi.nlm.nih.gov/pubmed/31640657
http://dx.doi.org/10.1186/s12889-019-7652-x
work_keys_str_mv AT kagujjemary implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons
AT mubianamuhaul implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons
AT mwambaeugenia implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons
AT muyoyetamonde implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons